HOME
SEARCH
RSS FEED
SUBSCRIBE
Major Neutralization Site of Hepatitis E Virus and Use of this Neutralization Site in Methods of Vaccination
Case ID:
TAB-538
Web Published:
12/6/2022
Description:
Hepatitis E is endemic in many countries throughout the developing world, in particular on the continents of Africa and Asia. The disease generally affects young adults and has a very high mortality rate, up to 20%, in pregnant women. This invention relates to the identification of a neutralization site of hepatitis E virus (HEV) and neutralizing antibodies that react with it. The neutralization site is located on a polypeptide from the ORF2 gene (capsid gene) of HEV. This neutralization site was identified using a panel of chimpanzee monoclonal antibodies that are virtually identical to human antibodies. Since this neutralization site is conserved among genetically divergent strains of HEV, the neutralizing monoclonal antibodies may be useful in the diagnosis, treatment and/or prevention of hepatitis E. Furthermore, immunogens that encompass this neutralization site may be used in vaccination to effectively prevent, and/or reduce the incidence of HEV infection. Polypeptides containing this neutralization site may be useful in evaluating vaccine candidates for the production of neutralizing antibodies to HEV.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Patent Status
Direct Link:
https://nih.technologypublisher.com/tech/Major_Neutralization_Site_of_Hepatit is_E_Virus_and_Use_of_this_Neutralization_Site_in_Methods_of_Vaccination
Category(s):
Collaboration
Licensing
Infectious Disease
Vaccines
Bookmark this page
Download as PDF
For Information, Contact:
Peter Soukas
Technology Licensing Specialist/TTPS
NIH Technology Transfer
301-496-2644
peter.soukas@nih.gov
Inventors:
Suzanne Emerson
Robert Purcell
Keywords:
DC5BXX
DCXXXX
DXXXXX
Hepatitis A
Hepatitis D
Hepatitis E
Home
|
Search
|
RSS
|
Subscribe
© 2024. All Rights Reserved. Powered by
Inteum